Cellectar (CLRB) director receives 25,000 stock options at $2.70 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. They vest in full on July 7, 2027, subject to his continued service, and this grant brings his reported option holdings from this award to 25,000 derivative securities.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
DRISCOLL FREDERICK W
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 25,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 25,000 options
Exercise price: $2.70 per share
Expiration date: July 7, 2036
+2 more
5 metrics
Options granted
25,000 options
Stock option award to director Frederick W. Driscoll
Exercise price
$2.70 per share
Strike price for the granted stock options
Expiration date
July 7, 2036
Option term end date for the grant
Vesting date
July 7, 2027
Options vest in full on this date, subject to service
Underlying shares
25,000 shares
Common stock underlying the stock option award
Key Terms
Stock option (right to buy), exercise price, Common stock, vesting
4 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 2.7000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common stock financial
"underlying_security_title: Common stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"This option shall vest in full on July 7, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did Cellectar Biosciences (CLRB) disclose for Frederick W. Driscoll?
Cellectar Biosciences reported that director Frederick W. Driscoll received a grant of stock options for 25,000 shares. These options are a compensation-related award, not an open-market share purchase or sale, and give him the right to buy common stock at a fixed price.
How many Cellectar (CLRB) stock options were granted to Frederick W. Driscoll?
Frederick W. Driscoll was granted stock options covering 25,000 shares of Cellectar common stock. The Form 4 identifies this as a derivative security award tied to the company’s common stock, increasing his option-based exposure by that amount through this grant.
What is the exercise price of Frederick W. Driscoll’s new Cellectar (CLRB) options?
The new stock options for Frederick W. Driscoll have an exercise price of $2.70 per share. This means he can choose to purchase Cellectar common stock at $2.70 per share once the options are vested and before they expire, subject to the award terms.
When do Frederick W. Driscoll’s Cellectar (CLRB) stock options vest and expire?
The granted stock options vest in full on July 7, 2027, provided Driscoll continues serving through that date. The options carry an expiration date of July 7, 2036, giving a long exercise window after vesting, according to the Form 4 disclosure and related footnote.
Is Frederick W. Driscoll’s Cellectar (CLRB) option grant an open-market buy or sell?
The filing describes this as a grant or award acquisition of stock options, not an open-market transaction. Driscoll did not buy or sell shares in the market; instead, he received 25,000 options as compensation with a defined exercise price and vesting schedule.